Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Publication year range
1.
Int Arch Occup Environ Health ; 78(2): 97-108, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15726396

ABSTRACT

OBJECTIVE: Workers in various industries can be exposed to polycyclic aromatic hydrocarbons (PAHs). The relationship between biomarkers of genotoxic risk, PAH compounds in air (ambient monitoring) and PAH metabolites in urine (internal exposure) were studied in 17 workers exposed to PAHs in a fireproof-material producing plant before and 3 months after the PAH profile was altered in the binding pitch. METHODS: Two biomarkers of exposure, specific DNA adducts of (+/-)-r-7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydrobenzo[a]pyrene (anti-BPDE) and non-specific DNA adduct of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodGuo) were determined in white blood cells (WBCs). In addition, DNA strand breaks were analysed in lymphocytes by single-cell gel electrophoresis in a genotoxic risk assessment. Sixteen PAH compounds in air were determined by personal air sampling, and hydroxylated metabolites of phenanthrene, pyrene and naphthalene were determined in urine. RESULTS: After substitution of the binding pitch the concentrations of benzo[a]pyrene in air decreased (P<0.01). No changes could be observed for pyrene, while levels of phenanthrene (P=0.0013) and naphthalene (P=0.0346) in air increased. Consequently, median DNA adduct rates of anti-BPDE decreased after alteration of the production material (from 0.9 to <0.5 adducts/10(8) nucleotides). No changes in the excretion of 1-hydroxypyrene in urine could be determined, whereas increased levels of 1-, 2+9-, 3- and 4-hydroxyphenanthrene (P<0.0001) and 1-naphthol and 2-naphthol (P=0.0072) were found in urine. In addition, a statistically significant increase in DNA strand break frequencies (P<0.01) and elevated 8-oxodGuo adduct levels (P=0.7819, not statistically significant) were found in the WBCs of exposed workers 3 months after the PAH profile in the binding pitch had been altered. CONCLUSION: The results presented here show that the increased concentration of naphthalene and/or phenanthrene in the air at the work place could induce the formation of DNA strand breaks and alkali-labile sites in WBCs of exposed workers.


Subject(s)
DNA Damage , Environmental Monitoring/methods , Leukocytes/drug effects , Occupational Exposure/adverse effects , Polycyclic Aromatic Hydrocarbons/toxicity , Adult , Air Pollutants/adverse effects , Air Pollutants/analysis , Biomarkers/blood , Biomarkers/urine , DNA Adducts/blood , DNA Adducts/urine , Humans , Male , Middle Aged , Mutagenicity Tests , Mutagens , Naphthalenes/toxicity , Naphthalenes/urine , Occupational Exposure/analysis , Phenanthrenes/toxicity , Phenanthrenes/urine , Polycyclic Aromatic Hydrocarbons/metabolism , Risk Assessment
2.
Cancer Radiother ; 7(5): 314-6, 2003 Oct.
Article in French | MEDLINE | ID: mdl-14522352

ABSTRACT

Angiocentric lymphoma of the face is a rare malignancy. During 11 years, only two patients were treated for a lymphoma of the face. The first patient, 31-year-old, had an angiocentric lymphoma of the nasal cavity, the second patient, 40-year-old, had an angiocentric lymphoma of the nasopharynx and the maxillary sinuses, with an extension the hard palate. According to the Ann Arbor classification, the disease was stage IEab and stage IIEbb, respectively. The first patient was treated by chemotherapy alone (COP regimen) and the second patient underwent combined chemotherapy (CHOP) and radiotherapy. The follow-up was marked by progression of the disease 7 and 9 months after the end of the treatment in the two cases. For the angiocentric lymphoma, treatment based on radiotherapy or chemotherapy alone or combined does not often provide local control and the overall survival rate does not exceed 40% at 5 years.


Subject(s)
Facial Neoplasms/pathology , Granuloma/pathology , Lymphoma/pathology , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Disease Progression , Facial Neoplasms/drug therapy , Female , Granuloma/drug therapy , Humans , Lymphoma/drug therapy , Neoplasm Staging , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL